FDA Measures Naloxone Price Trend In Considering Wider Availability

Even though FDA cannot consider drug pricing, it gives research of naloxone sales to inform workshop on uptake and use. Amphastar’s naloxone prices are being scrutinized by state officials and a House member.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America